Tuberculosis in kidney transplant recipients: A case series

Table 2 Post-transplant patient characteristics and outcomes

	Patient 1	Patient 2	Patient 3	Patient 4
INH prophylaxis	No	No	Yes	No
T cell depleting antibody	Yes	Yes	Yes	Yes
Immunosuppressive	Tacrolimus, MMF	Tacrolimus, MMF	Tacrolimus, MMF	Tacrolimus, MMF
Corticosteroid	No	Yes	Yes	Yes
Acute rejection (6 mo prior to TB diagnosis)	No	No	No	No
Clinical features	Fever, palpitations, cervical LN	Fever, shortness of breath, cough	Fever, acute kidney injury	Fever, shortness of breath, leg swelling
TB site	Disseminated	Pulmonary	Extra-pulmonary	Disseminated
Time to symptom onset (mo)	11.5	2	9	2
Time to diagnosis, post-transplant (mo)	12	3	11	3
Treatment regimen	RIPE	None	RIPE-M	RIPE-M, Amikacin
Treatment duration (mo)	6.5	N/A	6	7
Adverse drug reaction	Hepatotoxicity	N/A	None	Neurologica,vision loss
Other complication	HBV reactivation, acute liver injury	Septic shock, MAS	None	VTE, IRIS, allograft failure
Outcome	Cured	Death	Cured	Death

INH: Isoniazid; MMF: Mycophenolate mofetil; TB: Tuberculosis; LN: Lymphadenopathy; RIPE: Rifampin, isoniazid, pyrazinamide, ethambutol; RIPE-M: Rifampin, isoniazid, pyrazinamide, ethambutol, moxifloxacin; HBV: Hepatitis B virus; MAS: Macrophage activation syndrome; VTE: Venous thromboembolism; IRIS: Immune reconstitution inflammatory syndrome.